## Drug Summary
Phylloquinone, also known by brand names such as Aqua-Mephyton and Konakion, is a fat-soluble form of vitamin K1. It plays a critical role in blood coagulation by serving as a cofactor for the enzyme Î³-carboxylase, which is essential for the activation of clotting factors II, VII, IX, and X. The drug is used to treat coagulation disorders caused by a deficiency of vitamin K or interference in vitamin K activity, which can arise from various conditions including dietary deficiency, antibiotic use, and diseases affecting fat absorption. Phylloquinone's pharmacokinetics varies with its formulations; oral formulations show moderate bioavailability, while parenteral forms are highly bioavailable. The pharmacodynamics of phylloquinone involves a long duration of action due to its recycling in the liver, significant increase in clotting factor activity, and potentially non-coagulation roles in bone health and vascular calcification are under investigation.

## Drug Targets, Enzymes, Transporters, and Carriers
Phylloquinone acts primarily through the enzyme gamma-carboxylase (GGCX), enhancing the attachment of carboxyl groups to glutamate residues on precursors of vitamin K-dependent clotting factors, thereby facilitating their activation by binding calcium ions. It also impacts osteocalcin (BGLAP), a protein secreted by osteoblasts and involved in bone formation, though its precise non-coagulative roles remain under examination. The metabolism of phylloquinone is facilitated by several enzymes including CYP4F2, which initiates breakdown via omega-hydroxylation of its phytyl side chain. Post hydroxylation, the compound undergoes further cleavage and glucuronidation before elimination. The vitamin K cycle, crucial for its activity and recycling, involves VKORC1 for the reduction of vitamin K epoxide back to vitamin K.

## Pharmacogenetics
Pharmacogenetic factors play a significant role in the effectiveness and safety of phylloquinone. Variants in genes such as VKORC1 and CYP4F2 can influence the pharmacokinetics and dynamics of vitamin K. VKORC1 polymorphisms affect the efficiency of vitamin K recycling, which is crucial for maintaining adequate levels of reduced vitamin K and sustaining gamma-carboxylation of clotting factors. CYP4F2 polymorphisms alter the metabolic clearance of vitamin K, thereby impacting serum levels and availability for clotting processes. These genetic variations can affect dosing requirements and risk of adverse effects, particularly in the context of anticoagulation therapy, emphasizing the need for genotype-guided dosing strategies in certain populations to optimize therapy and reduce the risk of bleeding or clotting complications.